We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
EMA requires long-term monitoring of Vocabria (cabotegravir + rilpivirine) due to risks of hepatotoxicity, pregnancy outcomes, and resistance. Learn about the findings and implications.
